Results 131 to 140 of about 1,461,609 (326)

Antibody Engineering for Pursuing a Healthier Future [PDF]

, 2017
Since the development of antibody-production techniques, a number of immunoglobulins have been developed on a large scale using conventional methods. Hybridoma technology opened a new horizon in the production of antibodies against target antigens of ...
Abdullah F. U. H. Saeed, Rongzhi Wang, Shihua Wang, Sumei Ling   +3 more
core   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy

Advanced Science, EarlyView.
B‐cell lymphomas are aggressive malignancies with limited treatment options. A bispecific nanosystem (biHSNPs) is developed, leveraging silica nanoplatforms to conjugate antibodies targeting immune effector cells and B‐cell antigens. biHSNPs form artificial immunological synapses, activating cytotoxic responses and suppressing tumor proliferation. This
Yefeng Shen, Xin Li, Jingnan Wu, Yuru Ma, Sven Borchmann, Zhenguo Cheng, Yaohe Wang, Yongliang Zhao, Jian Song, Boyu Luo, Xiuyun Liu, Yue Teng, Zhiyuan Shi   +12 more
wiley   +1 more source

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

American Journal of Hematology, EarlyView.
9% of patients with multiple myeloma achieve 15‐year progression‐free survival; Kaplan‐Meier curves for PFS (A) and OS (B). ABSTRACT The therapeutic advances during the last two decades have rendered multiple myeloma a chronic disease and, thus, it is important to identify patient subgroups which may have extremely favorable outcomes and optimize their
Meletios A. Dimopoulos, Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, Foteini Theodorakakou, Eirini Solia, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Stavroula Giannouli, Nikolaos Kanellias, Vassilis Koutoulidis, Maria Roussou, Angeliki Andrikopoulou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis   +17 more
wiley   +1 more source

Use of single-chain antibody derivatives for targeted drug delivery [PDF]

, 2016
Single-chain antibodies (scFvs), which contain only the variable domains of full-length antibodies, are relatively small molecules that can be used for selective drug delivery.
Ahmadzadeh, V., Erfani-Moghadam, V., Jaliani, H.Z., Khalili, M., Safdari, Y., Zarei, V.   +5 more
core   +1 more source

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates [PDF]

, 2015
Purpose: GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity ...
Carrasquillo, Jorge A., Chalasani, Sandhya, Cheal, Sarah M., Cheung, Nai-Kong V., Fung, Edward K., Guo, Hong-fen, Jungbluth, Achim, Larson, Steven M., Lee, Sang-gyu, O’Donoghue, Joseph, Punzalan, Blesida, Smith-Jones, Peter M., Wittrup, Karl Dane, Xu, Hong, Zanzonico, Pat B.   +14 more
core   +1 more source

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. [PDF]

Front Immunol, 2022
Hambach J, Mann AM, Bannas P, Koch-Nolte F.   +3 more
europepmc   +1 more source

Entwicklung eines Inkubationssystems für ein inverses Mikroskop zur Langzeitbeobachtung von Zellkulturen in gekammerten Objektträgern [PDF]

, 2001
Trifunctional bispecific antibodies open up new immunological possibilities in tumour treatment. Prior to clinical application, comprehensive investigations using animal models and in vitro examinations need to be done.
A. Buchner, Lindhofer H., R. Riesenberg, Riesenberg R., W. Feicht, Zeidler R.   +5 more
core   +1 more source

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

STAR Protocols, 2022
Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li, Alexander C. Partin, Liangjun Zhao, Irwin Chen, Mark L. Michaels, Zhulun Wang, Fernando Garces, Danyang Gong, Timothy P. Riley   +8 more
doaj  

Bispecific Antibodies Against HIV [PDF]

Cell, 2016
Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire   +3 more sources